Shopping Cart
Remove All
Your shopping cart is currently empty
BBC0403
😃Good
Catalog No. T88118Cas No. 2644662-83-7
Alias BBC 0403
BBC0403 is a selective BRD2 inhibitor that inhibits BRD2 and BRD2, suppressing NF-κB and MAPK signaling pathways. It can be used in osteoarthritis (OA) research.
BBC0403
😃Good
Purity: 98.15%
Catalog No. T88118Alias BBC 0403Cas No. 2644662-83-7
BBC0403 is a selective BRD2 inhibitor that inhibits BRD2 and BRD2, suppressing NF-κB and MAPK signaling pathways. It can be used in osteoarthritis (OA) research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $57 | In Stock | In Stock | |
| 5 mg | $133 | In Stock | In Stock | |
| 10 mg | $215 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $569 | In Stock | In Stock | |
| 100 mg | $786 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $141 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.15%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BBC0403 is a selective BRD2 inhibitor that inhibits BRD2 and BRD2, suppressing NF-κB and MAPK signaling pathways. It can be used in osteoarthritis (OA) research. |
| Targets&IC50 | BRD2 (BD2):7.64 μM (Kd), BRD2 (BD1):41.37 μM (Kd) |
| In vitro | BBC0403 is a selective BRD2 inhibitor with Kd values of 7.64 μM for BRD2 (BD2) and 41.37 μM for BRD2 (BD1).BBC0403 significantly inhibited the expression of catabolic factors, the production of prostaglandin E2 (PGE2) and the degradation of the extracellular matrix (ECM) after treatment with BBC0403 at 5 μM, 10 μM, and 20 μM for 12 h. BBC0403 inhibits catabolic factor expression, prostaglandin E2 (PGE2) production, and the degradation of ECM. and extracellular matrix (ECM) degradation. By blocking the NF-κB and MAPK signaling pathways, BBC0403 helps to alleviate the development of osteoarthritis (OA). [1] |
| In vivo | Weekly intra-articular injection of 5-10 μg/kg of BBC0403 for 6 weeks effectively prevented the degradation of osteoarthritic cartilage in a mouse model. [1] |
| Synonyms | BBC 0403 |
| Molecular Weight | 382.41 |
| Formula | C21H22N2O5 |
| Cas No. | 2644662-83-7 |
| Smiles | O=C1N=C(NC=2C=C(OC)C=C(OC)C12)C=3C=C(C(OC4COC4)=C(C3)C)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (52.3 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.23 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BBC0403 | purchase BBC0403 | BBC0403 cost | order BBC0403 | BBC0403 chemical structure | BBC0403 in vivo | BBC0403 in vitro | BBC0403 formula | BBC0403 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.